PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (PAMELA)
PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer
Sponsor: Novartis
Listed as NCT01973660, this PHASE2 trial focuses on Breast Cancer and remains completed. Sponsored by Novartis, it has been updated 9 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis
- SOLTI Breast Cancer Research Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Badajoz, Spain , Barcelona, Spain , Castellon, Spain , Cáceres, Spain , El Palmar, Spain , Fuenlabrada, Spain , L'Hospitalet de Llobregat, Spain , Lleida, Spain , Madrid, Spain , Palma de Mallorca, Spain and 6 more locations